Human ADAM9 PharmaGenie ELISA Kit (SBRS0227)

Researchers working on metalloprotease biology and tumor cell signaling rely on quantitative immunodetection of ADAM9 (A Disintegrin And Metalloproteinase domain-containing protein 9), a type I transmembrane sheddase that cleaves membrane-anchored substrates including HB-EGF, FGFR2, and amyloid precursor protein. The Assay Genie human ADAM9 immunoassay kit is configured for absorbance-based readout in a 96-assay microplate format, supporting cancer research, neuroinflammation studies, and wound-repair investigations where elevated ADAM9 expression has been linked to invasion and metastasis in breast, pancreatic, and hepatocellular carcinoma models.

Intended for research use only, the kit provides quantitative measurement of human ADAM9 in cell culture supernatant and in blood-derived human specimens. Laboratory workflows measuring ectodomain shedding, downstream integrin signaling, or response to metalloprotease inhibitors can integrate the assay alongside cell-based migration assays, siRNA knockdown validation, and small-molecule inhibitor screening. Each microplate ships with the coated wells, detection antibody, substrate, and reference standards needed for one full plate of human ADAM9 quantification.